Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4849652 | 0.83 | POLB (0.39) | ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL6208492 | 0.83 | ALDH1A1 (0.37) | ALDH1A1MAPTSMN1; SMN2KDM4EGAA | |
| SCHEMBL335134 | 0.76 | ALDH1A1 (0.60) | ALDH1A1MAPTSMN1; SMN2KDM4EGAA | |
| SCHEMBL4855010 | 0.76 | TARBP2 (0.42) | ALDH1A1MAPTKDM4EGAAHSD17B10 | |
| SCHEMBL4860361 | 0.73 | MAPT (0.38) | ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL4857813 | 0.72 | GLP1R (0.42) | ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL8806635 | 0.72 | KDM4E (0.42) | ALDH1A1SMN1; SMN2KDM4EGAAHSD17B10 | |
| SCHEMBL4861845 | 0.71 | GLP1R (0.36) | ALDH1A1MAPTCYP1A2TSHR | |
| SCHEMBL4857831 | 0.71 | KMT2A (0.37) | ALDH1A1MAPTSMN1; SMN2KDM4EGAA | |
| SCHEMBL4862703 | 0.70 | GLP1R (0.42) | ALDH1A1MAPTKDM4EGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456192-B2 | 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2008-11-25 | — | — | US | claimed |
| EP-1440075-B1 | NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF | PF MEDICAMENT (FR) | 2005-06-08 | — | — | EP | claimed |
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2005-04-14 | — | — | US | claimed |
| US-7456192-B2 | 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2008-11-25 | — | — | US | disclosed |
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | AOC3, MAOB, AOC1 | ALDH1A1 1130/4885MAPT 4210/4885SMN1; SMN2 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.